###### Significance of this study

What is already known on this subject?
======================================

-   Functional dyspepsia (FD) is heterogeneous in its aetiology, pathogenesis and treatment responses.

-   FD has been subdivided into epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) by the Rome III Consensus in an attempt to guide therapy.

-   The subdivision was based on post hoc analysis and warrants more clinical data from different ethnic populations to support the distinct aetiopathogenesis of the two subgroups.

What are the new findings?
==========================

-   PDS and EPS shared some common risk factors including younger age, non-steroidal anti-inflammatory drugs, anxiety and concomitant IBS.

-   *H. pylori*, unmarried status, sleep disturbance, depression, and less coffee consumption were associated with PDS, but not with EPS.

-   The association of *H. pylori* with PDS was probably attributed to the more severe gastric atrophy at the antrum and the higher prevalence of CagA positive *H. pylori* strains.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Different risk factors exist for subgroups of FD based on the Rome III criteria, indicating the distinct aetiopathogenesis of the subdivisions of FD that might necessitate different therapeutic strategies.

Introduction {#s1}
============

Functional dyspepsia (FD), a common but heterogeneous disease, remains a great burden to the healthcare system.[@R1] Numerous pathophysiological mechanisms, such as delayed gastric emptying, impaired gastric accommodation to a meal,[@R6] [@R7] visceral hypersensitivity to gastric distension,[@R8] [@R9] *Helicobacter pylori* infection,[@R10] psychosocial factors and central nervous system dysfunction,[@R14] and lifestyle factors have been shown to be involved in the pathogenesis of FD.[@R17] Due to its complexity in pathogenesis, treatment for FD remains a challenge in clinical practice.[@R2] [@R4] [@R21] [@R22] Although several treatment strategies, including testing and treatment for *H. pylori*, use of proton pump inhibitors, prokinetic agents and antidepressants have been shown to be effective in FD, each strategy is only effective in a small proportion of patients with FD.[@R2] [@R4] [@R21] [@R22]

In order to simplify the intricate heterogeneity of this symptom complex and to guide the treatment, the Rome III Consensus proposed the subdivision of FD into two subgroups: the epigastric pain syndrome (EPS) which is characterised by epigastric pain and burning, and the postprandial distress syndrome (PDS) which is characterised by postprandial fullness and early satiety.[@R1] [@R4] However, the subdivision of EPS and PDS was based on post hoc factor analysis of epidemiologic and pathophysiologic studies that used the Rome II definition without direct supporting scientific evidence.[@R1] [@R4] Therefore, it is crucial to elucidate whether there are distinct aetiologies and pathogenesis underlying the two subdivisions.

However, relatively few studies have investigated the differential pathogenesis in subgroups of FD according to the Rome III definition.[@R23] Increased recruitment of eosinophils in the duodenum has been observed in patients with PDS, but not EPS, in several studies.[@R4] [@R23] [@R24] Shindo *et al*[@R25] showed that lower acylated ghrelin levels might result in delayed gastric emptying in patients with PDS, but not with EPS. By contrast, Haag *et al*[@R26] reported no difference in delayed gastric emptying between PDS and EPS, while Kusano *et al*[@R27] showed rapid gastric emptying in PDS. Although previous epidemiological studies and meta-analysis of randomised trials supported the association of *H. pylori* with FD, whether it has differential roles in EPS and PDS remains poorly understood.[@R10] Besides, few studies addressed the impact of severity of gastric inflammation in the EPS and PDS subgroups.[@R13] [@R28] Recently, distinct psychopathological and personality traits have been reported in patients with PDS and EPS.[@R14] [@R15] Aro *et al*[@R14] showed differential associations of anxiety with PDS, but not with EPS. We previously identified that PDS, but not EPS, was independently associated with psychopathological stress, specifically in somatisation, depression and phobia.[@R15] Nevertheless, we did not recruit healthy controls and were therefore not able to confirm the association of psychopathology with FD as a whole in that study.[@R15] Furthermore, we did not assess the role of *H. pylori* in FD.[@R15]

Accordingly, in the present study we aimed to comprehensively explore the pathophysiological mechanisms, including psychopathology traits, *H. pylori* infection, virulence genotypes of *H. pylori*, severity of gastric inflammation and lifestyle factors underlying the two distinct subgroup syndromes of FD.

Materials and methods {#s2}
=====================

Setting and study subjects {#s2a}
--------------------------

This multicentre, prospective study was conducted at the National Taiwan University Hospital (NTUH) in northern Taiwan and its Yun-Lin Branch in mid-west Taiwan from January 2010 to May 2012. Although these two hospitals were referral centres in these two regions, patients can visit the two centres as open access clinics without referral from primary care physicians. Consecutive adult patients with dyspeptic symptoms at outpatient clinics were invited to be assessed with the standard Rome III diagnostic questionnaire. Consecutive asymptomatic subjects who underwent gastric cancer screening in the two hospitals were enrolled as healthy controls. All patients and controls underwent detailed history taking, including demographic data, lifestyle factors, and the 5-item Brief Symptom Rating Scale (BSRS-5), a validated short form of the BSRS for the evaluation of psychiatric distress and personality traits.[@R30] They also underwent oesophagogastroduodenoscopy (OGD) and laboratory check-up to exclude organic disease or other metabolic disorders. All subjects with the following conditions were excluded: (1) age less than 20 years; (2) presence of organic disorders such as ulcers (defined as mucosal defect of 3 mm or greater), ulcer scar, erosive oesophagitis, Barrett\'s oesophagus and malignancy on OGD survey (however, patients with erosions (defined as mucosal defect less than 3 mm) were not excluded); (3) concurrent severe illness, including malignancy at any sites, diabetes mellitus, advanced chronic kidney disease, liver cirrhosis and porphyria; (4) history of abdominal surgery; (5) bleeding tendency or current use of anticoagulants; and (6) regular use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors (PPI) for more than 1 month. The study protocol was approved by the institutional review boards of NTUH. Written informed consent was obtained from all patients prior to enrolment.

Rome III diagnostic questionnaire and symptoms definition {#s2b}
---------------------------------------------------------

The Chinese version of the questionnaire was translated from the original Rome III FD module. It was reviewed by three investigators (YCH, JML and MSW), and scrutinised by two native Chinese speakers without medical background to confirm the fidelity of translation and to ensure that the text was easy to read and understand.[@R15] Details of this questionnaire were described in our previous study.[@R15] In brief, the questionnaire consists of 18 questions, which allows the diagnosis of FD and its two subgroups, PDS and EPS, which may coexist by definition. FD was defined as the presence of postprandial fullness/early satiation or pain/burning more than once per week, in the last 3 months according to the Rome III criteria.[@R1] Patients with typical reflux symptoms (heartburn/acid regurgitation), defined as moderate and which occurred more than 2 days per week, were excluded according to the Rome III criteria.[@R1] Patients with endoscopically confirmed erosive oesophagitis were also excluded. Non-prominent reflux symptoms may coexist with dyspeptic symptoms. However, patients fulfilling the criteria for functional disorder of the gallbladder and sphincter of Oddi were excluded. Well trained research assistants interviewed the patients to help them complete the questionnaires. IBS was defined as the presence of abdominal pain or discomfort at least 3 days per month in the last 3 months, associated with at least two of the following bowel habit changes: stool frequency, stool form, or symptoms relieved after defaecation according to the Rome III criteria.[@R1]

Determination *H. pylori* infection, virulence genotypes and severity of gastric inflammation {#s2c}
---------------------------------------------------------------------------------------------

All patients underwent serology testing, histological examination, rapid urease test, and culture; the healthy controls underwent the ^13^C-urea breath test (^13^C-UBT) to examine *H. pylori*. Individuals who fulfilled one of the following criteria were defined as having *H. pylori* infection: (1) a positive ^13^C-UBT; (2) a positive culture; or (3) at least two positive findings among rapid urease test, histology and serum antibody. The severity of gastritis was graded by the updated Sydney Classification. The CagA gene and the VacA signal region (s1/2) and midregion (m1/2) mosaics were determined by PCR as described previously.[@R31]

Evaluation of psychiatric distress and lifestyle factors {#s2d}
--------------------------------------------------------

BSRS-5 consisted of five parameters---sleep disturbance, anxiety, hostility, depression and inferiority---and was a validated instrument to assess psychiatric distress and personality traits.[@R30] The internal consistency coefficients of BSRS-5 ranged from 0.77 to 0.90.[@R30] Demographic data and lifestyle factors (including occupation, marital status, blood type, body mass index, education level, exercise habits, vegetarians, medication history, cigarette smoking, and consumption of alcohol, betel nut, tea and coffee were recorded in all patients and controls). Smoking was divided into never and ever (including those who are smokers or who quit less 5 years ago). Alcohol drinking was divided into never/rare and regular drinking (more than once a week, and \>40 g per week). Betel nut chewing was divided into never/rare and regular (including who were chewing or who quit less than 5 years ago). Habits of tea, coffee and exercise were divided into never/rare (less than three times a month) and regular (more than once a week). The different kinds and quantities of tea, coffee and exercise were all noted. We excluded patients who took NSAIDs/aspirin regularly (defined as more than three times per week). We also excluded non-regular users who had taken NSAIDs/aspirin for more than 10 days in the month prior to enrolment. Non-regular users who took NSAIDs/aspirin for less than 10 days in the month prior to enrolment were classified as 'ever' NSAIDs/aspirin recent consumption.

Statistical methods {#s3}
===================

Categorical data were compared using the χ^2^ test or Fisher\'s exact test as appropriate. Continuous data were compared with Student\'s t test and expressed as mean (SD) or one-way analysis of variance (ANOVA) as appropriate. Logistic regression analysis was used to identify risk factors of uninvestigated dyspepsia, FD and its subgroups, as compared to healthy controls. Adjusted ORs and 95% CIs were calculated. Those with p values of less than 0.05 were further included in the multivariable logistic regression models. Multiple testing adjustment with the Holm method was applied for controlling type I error. All statistical tests were two-tailed and p values of less than 0.005 were considered significant after adjustment for multiple testing. Statistical analyses were performed using SPSS V.12.0 for Windows.

Results {#s4}
=======

Enrolment of patients with dyspepsia and controls {#s4a}
-------------------------------------------------

During the study period, 2378 patients with dyspeptic symptoms were screened for eligibility ([figure 1](#GUTJNL2014308114F1){ref-type="fig"}). Among the 771 individuals who had uninvestigated dyspepsia for more than 3 months, 280 patients (36.3%) had organic lesions on OGD. Therefore, 491 patients met the diagnostic criteria of FD. Of the 1168 asymptomatic healthy subjects assessed for eligibility, 137 were excluded, because of a history of malignancy in 46, diabetes mellitus in 86, chronic kidney diseases in 2 and liver cirrhosis in 3. A total of 1031 asymptomatic healthy subjects were eligible as controls. Among the 491 patients with FD, 298 (60.7%) and 353 (71.9%) fulfilled the diagnosis of EPS and PDS, respectively. A total of 169 (34.4%) had symptoms compatible with both PDS and EPS, whereas 9 (1.8%) patients with FD did not fit the diagnostic criteria of either PDS or EPS. In addition, 124 (25.3%) reported concomitant non-prominent reflux symptoms. The frequency, severity and associated symptoms are summarised in [table 1](#GUTJNL2014308114TB1){ref-type="table"}.

###### 

Symptom frequency, severity of subgroups of functional dyspepsia

                          Pure PDS (n=184)   Pure EPS (n=129)   Pure overlap (n=169)                                                    
  ----------------------- ------------------ ------------------ ---------------------- ------------ ----------- ---------- ------------ -----------
  Frequency                                                                                                                             
   ≥2 days/week           48 (26.1)          40 (21.7)          5 (2.6)                108 (83.7)   53 (31.4)   9 (5.3)    15 (8.9)     86 (50.9)
   Every day              55 (29.9)          29 (15.7)          7 (3.8)                21 (16.3)    63 (37.3)   12 (7.1)    17 (10.0)   83 (49.1)
  Severity                                                                                                                              
   Mild                   54 (29.3)          29 (15.8)          6 (3.3)                61 (47.3)    39 (30.2)   10 (5.9)   10 (5.9)     58 (34.3)
   Moderate               40 (21.7)          21 (11.4)          4 (2.1)                55 (42.6)    63 (48.8)   7 (4.1)    17 (10.1)    89 (52.7)
   Severe                 9 (4.9)            7 (3.8)            2 (1.1)                13 (10.1)    14 (10.6)   4 (2.4)    5 (3.0)      22 (13.0)
  Associated symptoms                                                                                                                   
   Nausea                 6 (3.3)            3 (1.6)            9 (4.9)                5 (3.9)      11 (6.5)    1 (0.6)    7 (4.1)      9 (5.3)
   Belching               5 (2.7)            3 (1.6)            6 (3.3)                3 (2.30      9 (5.3)     1 (0.6)    6 (3.6)      7 (4.1)
   Bloating               66 (35.9)          45 (24.5)          9 (4.9)                30 (23.2)    86 (50.9)   11 (6.5)   18 (10.7)    41 (24.3)
   Non-prominent reflux   31 (16.8)          18 (9.8)           5 (2.7)                28 (21.7)    25 (14.8)   15 (8.9)   2 (1.2)      42 (24.9)

Nine unspecific subgroup subjects were not included.

\*Both, subjects had typical symptom of postprandial fullness and early satiation.

EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.

![Flowchart of the study.](gutjnl-2014-308114f01){#GUTJNL2014308114F1}

We performed logistic regression analysis to explore the risk factors of uninvestigated dyspepsia, FD and its subgroups. The results of univariate analysis are shown in online supplementary tables S1 and S2, whereas the adjusted ORs are presented in [tables 2](#GUTJNL2014308114TB2){ref-type="table"} and [3](#GUTJNL2014308114TB3){ref-type="table"}.

###### 

Risk factors of uninvestigated dyspepsia and functional dyspepsia as compared with healthy controls; multivariate analysis

                                   No dyspepsia (n=1031)   Uninvestigated dyspepsia (n =771)   Functional dyspepsia (n=491)                                                   
  -------------------------------- ----------------------- ----------------------------------- ------------------------------ --------- -------------- ---------------------- ---------
  *Demographic factors*                                                                                                                                                       
  Sex                                                                                                                                                                         
   Male                            515 (50.0)              302 (39.2)                          1                              0.008     146 (29.7)     1                      \<0.001
   Female                          516 (50.0)              469 (60.8)                          1.52 (0.98 to 2.38)                      345 (70.3)     2.01 (1.16 to 3.47)    
  Age (years)                                                                                                                                                                 
   Mean (SD)                       51.79 (10.69)           46 (13.80)                          0.96 (0.94 to 0.98)            \<0.001   45.0 (13.30)   0.95 (0.93 to 0.98)    \<0.001
  Occupation                                                                                                                                                                  
   Unemployed                      354 (34.3)              250 (32.4)                          1                              0.786     168 (34.2)     1                      0.478
   White-collar                    372 (36.1)              246 (31.9)                          0.95 (0.61 to 1.49)            0.763     170 (34.6)     1.05 (0.63 to 1.75)    0.795
   Labourer                        305 (29.1)              275 (35.7)                          0.89 (0.55 to 1.43)            0.490     153 (31.2)     0.84 (0.48 to 1.47)    0.375
  Married status                                                                                                                                                              
   Married                         937 (90.9)              620 (80.4)                          1                              0.107     384 (78.2)     1                      0.147
   Never married                   94 (9.1)                151 (19.6)                          1.42 (0.77 to 2.64)                      107 (21.8)     1.42 (0.72 to 2.80)    
  Education level                                                                                                                                                             
   Below elementary                102 (9.9)               124 (16.1)                          1                                        60 (12.2)      1                      
   Below senior high school        252 (24.4)              312 (40.5)                          0.77 (0.42 to 1.41)            0.228     193 (39.3)     0.95 (0.46 to 1.97)    0.831
   Above college                   677 (65.7)              335 (43.5)                          0.32 (0.17 to 0.60)            \<0.001   238 (48.5)     0.42 (0.20 to 0.88)    0.001
  *Lifestyle factors*                                                                                                                                                         
  BMI (kg/m^2^)                                                                                                                                                               
   Mean (SD)                       23.52 (3.19)            23.72 (7.63)                        1.02 (0.99 to 1.06)            0.081     22.94 (5.10)   1.00 (0.95 to 1.05)    0.872
  Smoking                                                                                                                                                                     
   Never                           831 (80.6)              545 (70.7)                          1                              0.032     381 (77.6)     1                      0.284
   Ever                            200 (19.4)              226 (29.3)                          1.49 (0.88 to 2.51)                      110 (22.4)     1.28 (0.68 to 2.41)    
  Alcohol consumption                                                                                                                                                         
   Never                           842 (81.7)              558 (72.4)                          1                              0.063     378 (77.0)     1                      0.216
   Ever                            189 (18.3)              213 (27.6)                          1.38 (0.85 to 2.24)                      113 (23.0)     1.29 (0.73 to 2.29)    
  Betel nut chewing                                                                                                                                                           
   Never                           1017 (98.6)             683 (88.6)                          1                              \<0.001   452 (92.1)     1                      0.001
   Ever                            14 (1.4)                88 (11.4)                           6.31 (2.20 to 18.12)                     39 (7.9)       4.55 (1.30 to 15.91)   
  Tea consumption                                                                                                                                                             
   Never                           461 (44.7)              383 (49.7)                          1                              0.302     247 (50.3)     1                      0.213
   Ever                            570 (55.3)              388 (50.3)                          0.87 (0.59 to 1.28)                      244 (49.7)     0.82 (0.52 to 1.29)    
  Coffee consumption                                                                                                                                                          
   Never                           545 (52.9)              479 (62.1)                          1                              0.002     297 (60.5)     1                      0.011
   Ever                            486 (47.1)              292 (37.9)                          0.65 (0.44 to 0.97)                      194 (39.5)     0.66 (0.41 to 1.04)    
  Vegetarian                                                                                                                                                                  
   Never                           996 (96.9)              724 (93.9)                          1                              0.106     462 (94.1)     1                      0.319
   Ever                            35 (3.4)                47 (6.1)                            1.62 (0.70 to 3.73)                      29 (5.9)       1.41 (0.53 to 3.73)    
  Exercise habit                                                                                                                                                              
   Less/never                      361 (35.0)              488 (63.3)                          1                              \<0.001   297 (60.5)     1                      0.012
   Ever                            670 (65.0)              283 (36.7)                          0.51 (0.35 to 0.74)                      194 (39.5)     0.68 (0.44 to 1.05)    
  NSAIDs recent consumption                                                                                                                                                   
   Never                           997 (96.7)              598 (77.6)                          1                              \<0.001   383 (78.0)     1                      \<0.001
   Ever                            34 (3.3)                173 (22.4)                          5.96 (3.04 to 11.69)                     108 (22.0)     6.60 (3.13 to 13.90)   
  Aspirin recent consumption                                                                                                                                                  
   Never                           997 (96.7)              761 (98.7)                          1                              0.072     484 (98.6)     1                      0.343
   Ever                            34 (3.3)                10 (1.3)                            0.43 (0.11 to 1.61)                      7 (1.4)        0.61 (0.14 to 2.68)    
  Psychological factors (BSRS-5)                                                                                                                                              
  I. Sleep disturbance                                                                                                                                                        
   No                              619 (60.0)              280 (36.3)                          1                              \<0.001   161 (32.8)     1                      0.001
   Yes                             412 (40.0)              491 (63.7)                          1.76 (1.18 to 2.61)                      330 (67.2)     1.72 (1.09 to 2.73)    
  II\. Anxiety                                                                                                                                                                
   No                              727 (70.5)              321 (41.6)                          1                              \<0.001   169 (34.4)     1                      \<0.001
   Yes                             304 (29.5)              450 (58.4)                          2.82 (1.78 to 4.46)                      332 (64.8)     3.41 (2.01 to 5.77)    
  III\. Hostility                                                                                                                                                             
   No                              674 (65.4)              376 (48.8)                          1                              0.021     214 (43.6)     1                      0.176
   Yes                             357 (34.6)              395 (51.2)                          0.67 (0.41 to 1.09)                      277 (56.4)     0.76 (0.44 to 1.34)    
  IV\. Depression                                                                                                                                                             
   No                              759 (73.6)              389 (50.5)                          1                              0.001     225 (45.8)     1                      0.001
   Yes                             272 (26.4)              382 (49.5)                          1.80 (1.10 to 2.93)                      266 (54.2)     1.92 (1.10 to 3.33)    
  V. Inferiority                                                                                                                                                              
   No                              891 (86.4)              579 (75.1)                          1                              0.007     366 (74.5)     1                      0.001
   Yes                             140 (13.6)              192 (24.9)                          0.59 (0.34 to 1.02)                      125 (25.5)     0.48 (0.26 to 0.90)    
  *Other factors*                                                                                                                                                             
  *H. pylori*                                                                                                                                                                 
   No                              652 (63.2)              413 (53.6)                          1                              \<0.001   295 (60.1)     1                      0.003
   Yes                             379 (36.8)              358 (46.4)                          1.88 (1.30 to 2.73)                      196 (39.9)     1.60 (1.03 to 2.48)    
  IBS                                                                                                                                                                         
   No                              999 (96.9)              620 (80.4)                          1                              \<0.001   347 (70.7)     1                      \<0.001
   Yes                             32 (3.1)                151 (19.6)                          6.09 (3.12 to 11.91)                     144 (29.3)     6.89 (3.41 to 13.94)   

ORs and 99.5% CIs calculated using a multivariate logistic regression model adjusted for all variables of p values less than 0.05 in the online supplementary table S1 and multiple testing adjustment (Holm method).

BMI, body mass index; BSRS-5, 5-item Brief Symptom Rating Scale; IBS, irritable bowel syndrome.

###### 

Risk factors of subgroups of functional dyspepsia as compared with healthy controls; multivariate analysis

                                     No dyspepsia (n=1031)   Pure PDS (n=184)   Pure EPS (n=129)       Pure overlap (n=169)                                                                                          
  ---------------------------------- ----------------------- ------------------ ---------------------- ---------------------- -------------- ----------------------- --------- -------------- ---------------------- ---------
  *Demographic factors*                                                                                                                                                                                              
  Sex                                                                                                                                                                                                                
   Male                              515 (50.0)              55 (29.9)          1                      0.011                  41 (31.8)      1                       0.009     47 (27.8)      1                      0.011
   Female                            516 (50.0)              129 (70.1)         2.08 (0.93 to 4.66)                           88 (68.2)      2.26 (0.94 to 5.44)                122 (72.2)    2.35 (0.92 to 6.04)    
  Age                                                                                                                                                                                                                
   Mean (SD)                         51.79 (10.69)           44 (13.83)         0.94 (0.91 to 0.97)    \<0.001                46 (13.12)     0.96 (0.93 to 1.00)     0.005     44 (12.87)     0.95 (0.91 to 0.98)    \<0.001
  Occupation                                                                                                                                                                                                         
   Unemployed                        354 (34.3)              55 (29.9)          1                      0.229                  39 (30.2)      1                       0.043     72 (42.6)      1                      0.415
   White-collar                      372 (36.1)              74 (40.2)          1.48 (0.71 to 3.08)    0.139                  46 (35.7)      0.54 (0.24 to 1.20)     0.031     46 (27.2)      1.45 (0.63 to 3.31)    0.211
   Labourer                          305 (29.1)              55 (29.9)          1.03 (0.46 to 2.32)    0.929                  44 (34.1)      0.52 (0.22 to 1.25)     0.037     51 (30.2)      1.39 (0.403.77)        0.287
  Married                                                                                                                                                                                                            
   Yes                               937 (90.9)              130 (71.0)         1                      \<0.001                103 (79.8)     1                       0.610     138 (86.7)     1                      0.882
   Never                             94 (9.1)                53 (29.0)          4.22 (2.02 to 8.81)                           20 (15.5)      1.23 (0.40 to 3.77)               31 (18.3)      1.06 (0.37 to 3.02)    
  Education                                                                                                                                                                                                          
   Below elementary                  102 (9.9)               18 (9.8)           1                                             17 (13.2)      1                                 23 (13.6)      1                      
   Below senior high school          252 (24.4)              67 (36.4)          1.19 (0.39 to 3.60)    0.658                  49 (38.0)      1.23 (0.37 to 4.09)     0.629     75 (44.4)      0.70 (0.24 to 2.02)    0.339
   Above college                     677 (65.7)              99 (53.8)          0.51 (0.17 to 1.56)    0.092                  63 (48.8)      0.61 (0.18 to 2.05)     0.250     71 (42.0)      0.22 (0.07 to 0.67)    \<0.001
  Blood type\*                                                                                                                                                                                                       
   A type                            264 (25.6)              44 (26.3)          1                                             30 (27.8)      1                                 46 (31.5)      1                      
   B type                            223 (21.6)              42 (25.1)          1.05 (0.45 to 2.46)    0.879                  27 (25.0)      1.17 (0.46 to 2.97)     0.640     25 (17.1)      0.782 (0.30 to 2.24)   0.580
   AB type                           56 (5.4)                15 (9.0)           1.68 (0.50 to 5.63)    0.230                  5 (4.6)        1.53 (0.33 to 7.13)     0.438     22 (15.1)      3.79 (1.15 to 12.48)   0.002
   O type                            435 (42.2)              66 (39.5)          0.75 (0.36 to 1.60)    0.290                  46 (42.6)      0.91 (0.40 to 2.04)     0.738     53 (36.3)      0.88 (0.39 to 1.99)    0.663
  *Lifestyle factors*                                                                                                                                                                                                
  BMI (kg/m^2^)                                                                                                                                                                                                      
   Mean (SD)                         23.52 (3.19)            22.55 (3.60)       0.98 (0.89 to 1.09)    0.633                  23.83 (7.63)   1.04 (0.98 to 1.11)     0.081     22.74 (4.02)   0.95 (0.85 to 1.05)    0.134
  Smoking                                                                                                                                                                                                            
   Never                             831 (80.6)              144 (78.3)         1                      0.731                  105 (81.4)     1                       0.679     124 (73.4)     1                      0.057
   Ever                              200 (19.4)              40 (21.7)          1.12 (0.44 to 2.86)                           24 (18.6)      0.85 (0.28 to 2.58)               45 (26.6)      2.00 (0.72 to 5.56)    
  Alcohol consumption                                                                                                                                                                                                
   Never                             842 (81.7)              138 (75.0)         1                      0.036                  105 (81.4)     1                       0.785     128 (75.7)     1                      0.296
   Ever                              189 (18.3)              46 (25.0)          1.80 (0.82 to 3.97)                           24 (18.6)      1.10 (0.42 to 2.88)               41 (24.3)      1.41 (0.56 to 3.52)    
  Betel nut                                                                                                                                                                                                          
   Never                             1017 (98.6)             174 (94.6)         1                      0.313                  120 (93.0)     1                       0.010     150 (88.8)     1                      0.001
   Ever                              14 (1.4)                10 (5.4)           1.97 (0.30 to 12.86)                          9 (7.0)        5.92 (0.85 to 41.21)              19 (11.2)      6.11 (1.24 to 30.22)   
  Coffee                                                                                                                                                                                                             
   Never                             545 (52.9)              119 (64.7)         1                      0.002                  75 (58.1)      1                       0.053     96 (56.8)      1                      0.227
   Ever                              486 (47.1)              65 (35.3)          0.49 (0.25 to 0.92)                           54 (41.9)      0.62 (0.30 to 1.24)               73 (43.2)      0.74 (0.37 to 1.49)    
  Exercise habit                                                                                                                                                                                                     
   Less/never                        361 (35.0)              105 (57.1)         1                      0.206                  80 (62.0)      1                       0.124     106 (62.7)     1                      0.012
   Ever                              670 (65.0)              79 (42.9)          0.76 (0.41 to 1.41)                           49 (38.0)      0.69 (0.35 to 1.36)               63 (37.3)      0.54 (0.27 to 1.07)    
  NSAIDs recent used                                                                                                                                                                                                 
   Never                             997 (96.7)              151 (82.1)         1                      \<0.001                99 (76.4)      1                       \<0.001   125 (74.0)     1                      \<0.001
   Ever                              34 (3.3)                33 (17.9)          5.30 (1.87 to 15.05)                          30 (23.3)      7.62 (2.77 to 20.95))             44 (26.0)      8.76 (3.28 to 23.40)   
  *Psychological factors (BSRS-5)*                                                                                                                                                                                   
  I. Sleep disturbance                                                                                                                                                                                               
   No                                619 (60.0)              47 (25.5)          1                      \<0.001                72 (55.8)      1                       0.221     39 (23.1)      1                      \<0.001
   Yes                               412 (40.0)              137 (74.5))        2.56 (1.29 to 5.07)                           57 (44.2)      0.73 (0.35 to 1.51)               130 (76.9)     3.10 (1.41 to 6.81)    
  II\. Anxiety                                                                                                                                                                                                       
   No                                727 (70.5)              56 (30.4)          1                      \<0.001                57 (44.2)      1                       0.001     53 (31.4)      1                      \<0.001
   Yes                               304 (29.5)              128 (69.6))        2.80 (1.34 to 5.88)                           72 (55.8)      2.88 (1.21 to 6.79)               116 (68.6)     4.36 (1.84 to 10.34)   
  III\. Hostility                                                                                                                                                                                                    
   No                                674 (65.4)              72 (39.1)          1                      0.118                  61 (47.3)      1                       0.924     74 (43.8)      1                      0.091
   Yes                               357 (34.6)              112 (60.9))        0.63 (0.28 to 1.44)                           68 (52.7)      1.03 (0.41 to 2.60)               95 (56.2)      0.58 (0.23 to 1.48)    
  IV\. Depression                                                                                                                                                                                                    
   No                                759 (73.6)              74 (40.2)          1                      0.003                  66 (51.2)      1                       0.062     79 (46.7)      1                      0.063
   Yes                               272 (26.4)              110 (59.8))        2.34 (1.04 to 5.36)                           63 (48.8)      1.82 (0.74 to 4.49)               90 (53.3)      1.81 (0.74 to 4.40)    
  V. Inferiority                                                                                                                                                                                                     
   No                                891 (86.4)              134 (72.8))        1                      0.070                  99 (76.7)      1                       0.009     126 (74.6)     1                      0.008
   Yes                               140 (13.6)              50 (27.2)          0.58 (0.24 to 1.36)                           30 (23.3)      0.38 (0.13 to 1.08)               43 (25.4)      0.40 (0.15 to 1.06)    
  *Other factors*                                                                                                                                                                                                    
  *H. pylori*                                                                                                                                                                                                        
   No                                652 (63.2)              102 (55.4)         1                      0.005                  77 (59.7)      1                       0.148     110 (65.1)     1                      0.646
   Yes                               379 (36.8)              82 (44.6)          1.86 (1.01 to 3.45)                           50 (40.3)      1.43 (0.72 to 2.84)               59 (34.9)      1.12 (0.55 to 2.28)    
  IBS                                                                                                                                                                                                                
   No                                999 (96.9)              129 (70.1)         1                      \<0.001                96 (74.4)      1                       \<0.001   116 (68.6)     1                      \<0.001
   Yes                               32 (3.1)                55 (29.9)          5.90 (2.53 to 14.66)                          33 (25.6)      7.43 (2.80 to 19.73))             53 (31.4)      7.19 (2.72 to 19.01)   

ORs and 99.5% CIs calculated using a multivariate logistic regression model adjusted for all variables of p values less than 0.05 in the online supplementary table S2 and multiple testing adjustment (Holm method).

\*Blood type was unknown in 53 with control group, 17 with PDS, 23 with EPS, 25 with overlap syndrome.

BMI, body mass index; BSRS-5, 5-item Brief Symptom Rating Scale; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.

Demographic characteristics among patients with FD and its subgroups {#s4b}
--------------------------------------------------------------------

Women had an increased risk of FD (OR 2.01; 99.5% CI 1.16 to 3.47) and a slightly higher risk of uninvestigated dyspepsia (OR 1.52; 99.5% CI 0.98 to 2.38) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed a trend of increased risk of pure PDS (OR 2.08; 99.5% CI 0.93 to 4.66), pure EPS (OR 2.26; 99.5% CI 0.94 to 5.44), and overlap syndrome (OR 2.35; 99.5% CI 0.92 to 6.04) in women, but the differences were not significant after adjustment for multiple testing ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Those who never married had an increased risk of pure PDS (OR 4.22; 99.5% CI 2.02 to 8.81) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Subjects with a higher education level (above college) had a reduced risk of both uninvestigated dyspepsia (OR 0.32; 99.5% CI 0.17 to 0.60) and FD (OR 0.42; 99.5% CI 0.20 to 0.88) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). In the subgroup analysis, however, the association remained significant only in the overlap syndrome (OR 0.22; 99.5% CI 0.07 to 0.67), but not in pure PDS (OR 0.51; 99.5% CI 0.17 to 1.56) or pure EPS (OR 0.61; 99.5% CI 0.18 to 2.05) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}).

Lifestyle factors among patients with FD and its subgroups {#s4c}
----------------------------------------------------------

Consumption of betel nuts was associated with increased risk of both uninvestigated dyspepsia (OR 6.31; 99.5% CI 2.20 to 18.12) and FD (OR 4.55; 99.5% CI 1.30 to 15.91) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed that betel nut chewing was only associated with the overlap syndrome (OR 6.11; 99.5% CI 1.24 to 30.22), but not with pure EPS (OR 5.92; 99.5% CI 0.85 to 41.21) or pure PDS (OR 1.97; 99.5% CI 0.30 to 12.86) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Consumption of coffee was associated with a lower risk of uninvestigated dyspepsia (OR 0.65; 99.5% CI 0.44 to 0.97) and a trend for an inverse association with FD (OR 0.66; 99.5% CI 0.41 to 1.04) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed that coffee was inversely associated with pure PDS (OR 0.49; 99.5% CI 0.25 to 0.92), but not with pure EPS (OR 0.62; 99.5% CI 0.30 to 1.24) and overlap syndrome (OR 0.74; 99.5% CI 0.37 to 1.49) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Regular exercise was associated with a lower risk of uninvestigated dyspepsia(OR 0.51; 99.5% CI 0.35 to 0.74) but the association with FD was statistically less significant (OR 0.68; 99.5% CI 0.44 to 1.05) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). It was unrelated to any subgroup of FD ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Recent consumption of non-steroidal anti-inflammatory drugs (NSAIDs), but not aspirin, was associated with increased risk of both uninvestigated dyspepsia (OR 5.96; 99.5% CI 3.04 to 11.69) and FD (OR 6.60; 99.5% CI 3.13 to 13.90) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). The associations remained significant for pure PDS (OR 5.30; 99.5% CI 1.87 to 15.05), pure EPS (OR 7.62; 99.5% CI 2.77 to 20.95) and overlap syndrome (OR 8.76; 99.5% CI 3.28 to 23.40) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}).

Psychopathology and personality traits among patients with FD and its subgroups {#s4d}
-------------------------------------------------------------------------------

Sleep disturbance was positively associated with both uninvestigated dyspepsia (OR 1.76; 99.5% CI 1.18 to 2.61) and FD (OR 1.72; 99.5% CI 1.09 to 2.73) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed that it was associated with pure PDS (OR 2.56; 99.5% CI 1.29 to 5.07) and overlap syndrome (OR 3.10; 99.5% CI 1.41 to 6.81), but not with pure EPS (OR 0.73; 99.5% CI 0.35 to 1.51) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Anxiety was positively associated with both uninvestigated dyspepsia (OR 2.82; 99.5% CI 1.78 to 4.46) and FD (OR 3.41; 99.5% CI 2.01 to 5.77) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}), as well as different subtypes of FD, including pure PDS (OR 2.80; 99.5% CI 1.34 to 5.88), pure EPS (OR 2.88; 99.5% CI 1.21 to 6.79) and overlap syndrome (OR 4.36; 99.5% CI 1.84 to 10.34) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Depression was positively associated with both uninvestigated dyspepsia (OR 1.80; 99.5% CI 1.10 to 2.93) and FD (OR 1.92; 99.5% CI 1.10 to 3.33) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed that it was associated with pure PDS (OR 2.34; 99.5% CI 1.04 to 5.36), but not with pure EPS (OR 1.82; 99.5% CI 0.74 to 4.49) and overlap syndrome (OR 1.81; 99.5% CI 0.74 to 4.40) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Hostility was not associated with uninvestigated dyspepsia, FD and its subgroups after multiple testing ([tables 2](#GUTJNL2014308114TB2){ref-type="table"} and [3](#GUTJNL2014308114TB3){ref-type="table"}). Inferiority was inversely associated with FD (OR 0.48; 99.5% CI 0.26 to 0.90) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis found no significant association with any subtype ([table 3](#GUTJNL2014308114TB3){ref-type="table"}).

*H. pylori*, virulence genotypes and severity of gastric inflammation among patients with FD and its subgroups {#s4e}
--------------------------------------------------------------------------------------------------------------

*H. pylori* infection was positively associated with both uninvestigated dyspepsia (OR 1.88; 99.5% CI 1.30 to 2.73) and FD (OR 1.60; 99.5% CI 1.03 to 2.48) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed that *H. pylori* infection was associated with only pure PDS (OR 1.86; 99.5% CI 1.01 to 3.45), but not with pure EPS (OR 1.43; 99.5% CI 0.72 to 2.84) or overlap syndrome (OR 1.12; 99.5% CI 0.55 to 2.28) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). The density of *H. pylori*, severity of intestinal metaplasia, and infiltration of neutrophils and monocytes were not significantly different among the three subgroups ([figure 2](#GUTJNL2014308114F2){ref-type="fig"}). However, there was a trend of more moderate and marked gastric atrophy at the antrum in the subgroup of pure PDS ([figure 2](#GUTJNL2014308114F2){ref-type="fig"}). Among *H. pylori* infected patients, we observed a trend (p=0.044) of more CagA positive strains in pure PDS (98.4%), as compared with pure EPS (89.1%) and the overlap syndrome (85.7%), as shown in [table 4](#GUTJNL2014308114TB4){ref-type="table"}.

###### 

Prevalence of virulence genotypes in subgroups of functional dyspepsia among *H. pylori* infected patients

  ---------------------------------------------------------------------
              Pure PDS\       Pure EPS\       Pure overlap\   p Value
              % (n)           % (n)           % (n)           
  ----------- --------------- --------------- --------------- ---------
  CagA                                                        0.044

   Positive   98.4% (60/61)   89.1% (41/46)   85.7% (42/49)   

   Negative   1.6% (1/61)     10.9% (5/46)    14.3% (7/49)    

  VacA                                                        0.749

   S1         95.1% (58/61)   97.9% (46/47)   95.8% (46/48)   

   S2         4.9% (3/61)     2.1% (1/47)     4.2% (2/48)     

  VacA                                                        0.318

   M1         60.0% (36/60)   45.5% (20/44)   56.9% (29/51)   

   M2         40.0% (24/60)   54.5% (24/44)   17.6% (9/51)    
  ---------------------------------------------------------------------

p Values calculated using χ^2^ test or Fisher\'s exact test as appropriate.

EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.

![Severity of gastritis reported according to the Sydney classification. \*Comparison among three distinct groups. †*H. pylori* infected group: Sydney classification of the body unknown in 25. ‡Non-*H. pylori* group: Sydney classification of the body unknown in 19.](gutjnl-2014-308114f02){#GUTJNL2014308114F2}

Overlap with other functional gastrointestinal disorders {#s4f}
--------------------------------------------------------

IBS was significantly associated with uninvestigated dyspepsia (OR 6.09; 99.5% CI 3.12 to 11.91) and FD (OR 6.89; 99.5% CI 3.41 to 12.94) ([table 2](#GUTJNL2014308114TB2){ref-type="table"}). Subgroup analysis showed that it was associated with the three subgroups of FD: pure PDS (OR 5.90; 99.5% CI 2.53 to 14.66), pure EPS (OR 7.43; 99.5% CI 2.80 to 19.73) and overlap syndrome (OR 7.19; 99.5% CI 2.72 to 19.01) ([table 3](#GUTJNL2014308114TB3){ref-type="table"}). Of the 141 FD subjects with concomitant IBS (including 26 constipation-predominant, 42 diarrhoea-predominant, 30 mixed-type, and 43 un-subtyped), the proportions of subtypes of IBS in FD were similar (p=0.25).

Discussion {#s5}
==========

There are several novel findings in the present study. We found that PDS and EPS shared common risk factors, including younger age, NSAIDs consumption, anxiety and concomitant IBS. Interestingly, we identified several risk factors distinct for PDS but not EPS, including *H. pylori* infection(OR 1.86 99.5% CI 1.01 to 3.45), unmarried status (OR 4.22 99.5% CI 2.02 to 8.81), sleep disturbance (OR 2.56 99.5% CI 1.29 to 5.07) and depression (OR 2.34 99.5% CI 1.04 to 5.36). Coffee consumption (OR 0.49 99.5% CI 0.25 to 0.92) was protective against PDS, but not EPS. We further showed that the association of *H. pylori* infection with PDS was probably mediated through the severity of gastric atrophy at the antrum. Interestingly, we also observed a higher prevalence of CagA positive *H. pylori* strains in PDS. These results collectively indicated that a distinct aetiopathogenesis underlies the subdivisions of FD according to the Rome III criteria.

The association of *H. pylori* with FD and its subgroups according to the Rome III criteria has been reported with inconsistent results in several observational studies.[@R13] [@R14] [@R17] Aro *et al*[@R14] and Zagari *et al*[@R17] found no significant association of *H. pylori* with FD in Western populations. Meta-analysis of randomised control trials revealed a small but significant reduction in dyspeptic symptoms after *H. pylori* eradication and the number needed to treat to cure was 14.[@R11] [@R13] Of the six trials that addressed the differential impacts of *H. pylori* eradication on symptom relief according to subgroups of FD,[@R12] [@R32] only two studies applied the Rome III definition.[@R12] [@R36] Of the three trials that showed a benefit of *H. pylori* eradication on FD, there were no significant differences between subgroups.[@R12] [@R34] [@R35] By contrast, Lan *et al*[@R36] reported a significant effect only in the EPS subgroup. The contradictory results might result from differences in the definitions of subgroups, efficacies of eradication regimens, *H. pylori* infection prevalence and the ethnic groups.[@R13] Further well designed randomised control trials are eagerly anticipated to assess whether therapeutic responses to *H. pylori* eradication differ according subgroups of FD.

There are several possible explanations for the different association of *H. pylori* infection with PDS and EPS. First, the higher prevalence of more virulent *H. pylori* strains in PDS might be contributory. This study found a higher prevalence of CagA positive *H. pylori* infection, which might account for more severe atrophic changes of the antrum, in patients with PDS. Second, the bacterial components and toxins of *H. pylori* infection might directly activate the peripheral sensory neurons and enhance the visceral hypersensitivity. This hypothesis was supported by a previous study which showed exaggerated postprandial gastric distension in *H. pylori* infected patients (80%), as compared with uninfected patients (33%).[@R37] Although we found an association of *H. pylori* with PDS in a hospital-based study in Taiwan, where the prevalence of *H. pylori* infection and CagA positive strains remains high, a further population-based study is warranted to estimate the relationship between *H. pylori* and FD in Asian populations.

The association of FD with psychopathology and personality traits has been reported in several studies.[@R4] [@R16] However, randomised trials failed to demonstrate consistent beneficial effects of anxiolytic agents or antidepressants, probably related to its heterogeneous aetiopathogenesis.[@R38] We found a significant association between depression and PDS, similar to the findings by Clauwaert *et al*[@R39] and Handa *et al.*[@R40] However, this was contradictory to a population-based study.[@R14] We also observed a higher prevalence of sleep disturbance in PDS, but not in EPS. This result was consistent with previous hospital-based studies, but was not found in population-based research.[@R41] By contrast, Yamawaki *et al* reported that sleep disturbance was similar in patients with EPS and those with PDS.[@R44] These inconsistent findings might be attributed to differences in the study population (eg, hospital vs community, East vs West), assessment tools, and ethnic and cultural differences. Nevertheless, these studies collectively showed that subgroups of FD differ in the association with psychological stress.

The mechanism underpinning the link with psychopathology remains poorly understood, but there are several plausible explanations. Perturbation of brain--gut signalling, including impaired sensory filtering, impaired cognitive circuits, or impaired descending modulatory system to physiological and salient/noxious stimuli, might be impaired by psychosocial factors, which in turn leads to impaired descending modulatory pathways.[@R16] Dysfunction of the autonomic nervous system, including hyperactive sympathetic tone and hypoactive vagal counterpart,[@R45] might lead to visceral hypersensitivity and cause dyspeptic symptoms. Some pathophysiological studies reported that impaired gastric accommodation was more common in patients with PDS than those with EPS.[@R4] Therefore, it is possible that the autonomic dysfunction associated with depression might impair gastric accommodation and produce symptoms of PDS.[@R45] Nevertheless, the results from our study led us to propose the hypothesis that antidepressants might be more effective in the subgroup with PDS. Further interventional trials are eagerly anticipated to prove this hypothesis.

Recent studies showed that the Rome III criteria cannot distinguish patients with organic diseases from those with FD.[@R46] [@R47] Our study had similar results, reporting that 36.3% (280/771) of cases of uninvestigated dyspepsia had structural lesions on OGD. More importantly, we also observed a significant overlap (n=169, 34.4%) among patients diagnosed with PDS and those with EPS. Whereas the EPS and PDS syndromes can be discriminated better in population-based studies, significant overlap was observed in hospital-based studies.[@R4] This indicated that the proportion of overlap might increase with disease severity and it is important to clarify whether those with the overlap syndrome have distinct pathogenesis. By revealing the association with NSAIDs, anxiety and IBS, our study showed that the overlap syndrome shared similar risk factors with pure EPS and pure PDS.

The impact of NSAIDs consumption on the risk of FD remains controversial. Our result agreed with Aro *et al*[@R14] that NSAIDs might influence the risk of FD and its subgroups. However, it has recently been shown that enteropathy can be detected by capsule endoscopy in 50--68% of NSAID users.[@R48] Therefore, some patients with 'FD' who have recently taken NSAIDs may actually have enteral lesions that are not detected on OGD. Besides, we found an interesting association of betel nut chewing with FD and the overlap subgroup. Betel nut chewing is a unique culture in Asia and has been shown to be a causal factor of squamous cell carcinoma of the oral cavity, oropharynx and oesophagus.[@R49] Interpretation of this association requires caution, particularly when the educational level is significantly lower in patients with FD. Since the habit of betel nut chewing is more common in blue-collar labourers than in white-collar workers, it could be a surrogate marker indicating low socioeconomic status (SES). Nevertheless, the association remained significant after adjustment for education and occupation, both of which could also stand for the SES. Besides, the association was significant for pure EPS and overlap syndrome, but not for pure PDS, indicating that this association was not related to lower SES alone. Clearly, this finding warrants further study for confirmation. Whether the association is directly related to the noxious stimuli of betel nuts or secondary to perturbation in visceral hypersensitivity needs to be clarified in future studies. The interesting protective effect of coffee consumption in PDS was probably related to the accelerated gastric emptying time of coffee.[@R50] [@R51] However, interventional trials are necessary to prove this hypothesis. We did not find an association between tea and FD in the present study. However, future studies are warranted to assess whether different kinds of tea have different biological effects in the pathogenesis of FD.

The strengths of this study included a large sample size, comprehensive analysis of each risk factors and endoscopic examination in all participants. We also assessed *H. pylori* status, its virulence genotypes and histological changes to explore the pathogenesis in different subgroups of FD. Nevertheless, there were some limitations. First, this was a hospital-based study which cannot be representative of the general population. However, the aim of the study is to analyse the risk factors of FD and its subgroups rather than to report the prevalence in the general population. Second, histological examination was not done in healthy controls. Nevertheless, this limitation did not compromise the finding that gastric atrophy was more severe in PDS patients than their EPS counterparts. Third, *H. pylori* status was determined by UBT alone in healthy controls, whereas FD patients underwent rapid urease test, histological examination, culture and serology. However, ^13^C-UBT alone is accurate in the diagnosis of *H. pylori* infection.[@R52] Another limitation was that income was not included in our analysis, although we did include occupation and education levels as markers of SES. In this study, we used the BSRS rather than HADs to quantify anxiety and depression, which might limit the comparability with other studies. However, we chose this instrument because it has been validated in our population. In this study, non-regular users who took NSAIDs/aspirin for less than 10 days in the month prior to enrolment were not excluded. Since NSAIDs/aspirin may also cause dyspepsia, patients who were taking NSAIDs/aspirin were excluded in some studies. However, patients taking NSAIDs/aspirin were not excluded in some population-based studies.[@R14] [@R17] Therefore, we did not exclude those who took NSAIDs/aspirin for less than 10 days in the month prior to enrolment. Finally, this is a cross-sectional study which cannot establish causal relationships. Further cohort studies and interventional trials are anticipated to test the hypotheses generated from this study.

In conclusion, PDS and EPS shared some common risk factors, including younger age, NSAIDs consumption, anxiety and IBS. However, PDS, but not EPS, was associated with *H. pylori* and psychological stress, including sleep disturbance and depression. We further demonstrated that the different association of *H. pylori* with PDS was probably mediated through more severe gastric atrophy at the antrum and higher prevalence of CagA positive *H. pylori* infection. In addition, coffee consumption was protective against PDS but not EPS. Our results collectively implicate the presence of distinct aetiopathogenesis in the subdivisions of FD according to the Rome III criteria. Further randomised control trials are eagerly anticipated to test whether the therapeutic responses to *H. pylori* eradication and antidepressants differ according to the FD subgroup.
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